Navigation Links
KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results
Date:8/11/2008

M) will make a significant contribution to Ther-Rx revenues during the second half of fiscal 2009.

ETHEX Corporation -- 53% Net Sales Growth Due to Metoprolol Succinate

ETHEX Corporation net sales of $92.3 million in the first quarter represented a 52.6% increase compared to the prior year first quarter of $60.5 million. Sales growth during the quarter was impacted by volume growth from the sale of all four strengths of metoprolol succinate extended-release tablets, which contributed $35.5 million in net revenues during the quarter, offset in part by the reduced level of sales from our discontinued cough/cold product line.

ETHEX's cough/cold product line, except for one product, was discontinued earlier this calendar year following a shift in FDA policy on products containing guaifenesin. Our currently marketed generic cough/cold product generated net revenues of $0.5 million during the quarter, compared with sales of the entire cough/cold product line of $9.3 million for the first quarter of fiscal 2008.

ETHEX's profitability remained strong for another quarter as measured by its gross profit margins of 60.5%, compared to gross margins of 56.0% in the first quarter of fiscal 2008.

The ETHEX pipeline remains strong. Last year we filed 16 ANDA's and this year we expect to file another 16 ANDA's. During this fiscal year, we expect six ANDA approvals, following five ANDA approvals received by KV in our preceding fiscal year. In addition, ETHEX believes it is the first to file for a number of Paragraph IV generic products with significant revenue contribution potential.

Outlook for the Year

The Company currently expects to report net revenue of between $650 million and $675 million and net income per diluted Class A share of between $1.65 and $1.75 for the fiscal year ending March 31, 2009. Although KV historically has not issued revenue or earnings guidance, in light of potential competitive challenges related to certain
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 According to court documents, ... owner of The Marcal Group (TMG), met with ... (HMG). A contract, as well a broad project outline, were ... as well as branding services and marketing. , ... by HMG throughout the course of the project, praise was ...
(Date:7/28/2014)... Downers Grove, IL (PRWEB) July 28, 2014 ... marketing company for mental health professionals, announced today its ... Family Therapy (IAMFT). This new relationship allows TherapySites ... IAMFT members, adding exclusive benefits and promotional offers. , ... business is being done today. With nearly 3 ...
(Date:7/28/2014)... July 28, 2014 According to the Heartburn ... a comprehensive guide that will help people get rid of ... all the necessary information about heartburn and acid reflux. In ... about heartburn , and risk factors for reflux disease. ... help people get rid of symptoms of reflux disease naturally ...
(Date:7/28/2014)... July 28, 2014 Shore Points Capital ... its investment in Loftware, Inc., through a recapitalization of ... Points was the lead investor in Loftware for over ... become the leading international provider of enterprise level software ... been a great investment for us, and we are ...
(Date:7/27/2014)... 2014 Hyaluronic Acid can hold 1,000 ... key to the power of Hyaluronic Serums. , "Hyaluronic ... founder of Sublime Beauty®. "But like collagen, it diminishes ... ours improves skin moisture-retention and radiance." , Hyaluronic ... a healthy and beautiful look. Key Ingredients in the ...
Breaking Medicine News(10 mins):Health News:Calko Medical Center Loses Website Twice over Non-Payment, According to Court Documents 2Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Shore Points Capital Announces Sale of Portfolio Company Loftware 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2
... over past 20 years due to suffocation, strangulation , ... accidental injury or death associated with crib bumper pads ... University School of Medicine in St. Louis. , Many ... protect babies from injury. But the researchers reviewed U.S. ...
... 2007 Late-breaking results from the ENDEAVOR IV trial, ... the Cardiovascular Research Foundation, show that the Endeavor zotarolimus-eluting ... overall safety profile (equivalent rates of death, heart attack, ... 1 year. , In addition, the Endeavor stent ...
... Lack Proper Healthcare Coverage, SAN FRANCISCO, ... Chapter of Autism Speaks today announced the ... Commission on,Autism,s recommendations to ensure appropriate and ... These recommendations were,finalized and presented to the ...
... MINNEAPOLIS, Oct. 22 Building upon its impressive ... laying out,a global vision, which will propel it ... orthopaedic research, education and new product,innovation, will solidify ... Over the next year, MORF will be ...
... than 450 people gathered on,Tuesday, October 9, at The ... 18th Annual CATCH Night of Champions. The event,featured a ... ceremony. The,event raised $225,000, with more than $38,000 raised ... been a major supporter of the charity since,1989, and ...
... has significantly increased life expectancy in early tests of ... most aggressive form of brain cancer in adults − ... Mayo Clinic in Jacksonville. , The vaccine represents a ... says neurosurgeon Kent New, M.D., Ph.D., who will be ...
Cached Medicine News:Health News:Crib Bumper Pads Too Risky for Baby 2Health News:ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent 2Health News:San Francisco Bay Area Autism Speaks Chapter Endorses Blue Ribbon Commission on Autism Recommendations for Equitable Insurance Coverage for Children With Autism 2Health News:San Francisco Bay Area Autism Speaks Chapter Endorses Blue Ribbon Commission on Autism Recommendations for Equitable Insurance Coverage for Children With Autism 3Health News:Mayo Clinic tests novel vaccine for aggressive brain tumors 2
(Date:7/25/2014)... YORK , July 25, 2014  Smile Train ... to showcase their Virtual Surgery Simulator among leading ... which will take place in Washington, D.C. ... the Performing Arts. "Smile Train is ... alongside the talented community of innovators in health and ...
(Date:7/25/2014)... 2014 GrowBLOX Sciences, Inc. (OTCQB: GBLX) is pleased ... ("MOU") with LaurelCo, LLC, an Illinois ... cultivation and dispensary medical marijuana licenses in the state of ... will acquire a 20% equity interest in LaurelCo, LLC in ... growing chambers, as well as all technology related to the ...
(Date:7/25/2014)...  Solanbridge Group Inc (OTC: SLNX) is pleased to ... Buzznbrewz.com and the Letter of Intent issued on July ... Purchase Agreement. Charles R. Shirley , ... have Mr. David Pecoraro and Buzznbrewz.com join ... private sector and developed a tremendous network of contacts ...
Breaking Medicine Technology:Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
... 2011 Caliper Life Sciences, Inc. (NASDAQ: ... for life science companies, today announced that Kevin Hrusovsky, President ... BioConference Live event, which was held on October 26, and ... Forum on October 27 held at Harvard Medical School. ...
... Conn., Nov. 7, 2011 Boehringer Ingelheim Pharmaceuticals, Inc. ... a Phase 2b study, SOUND-C2, that showed the combination ... compounds – the protease inhibitor BI 201335 and the ... successful in reducing viral load below the lower limit ...
Cached Medicine Technology:Caliper CEO Kevin Hrusovsky Presented Vision for Revolutionizing Medicine 2Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 2Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 3Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 4Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: